Related content

Ibandronate: once-monthly and intravenous dosing options for osteoporosis treatment

By Emkey Ronald  

Women's Health, Vol. 2, Iss. 3, 2006-05 ,pp. : 341-349

Future Medicine

Access to resources Recommend Favorite

Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate

By Gold Deborah T.   Safi Wael   Trinh Haian  

Current Medical Research and Opinion, Vol. 22, Iss. 12, 2006-12 ,pp. : 2383-2391

Informa Healthcare

Access to resources Recommend Favorite

Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg

By Epstein S.   Jeglitsch M.   McCloskey E.  

Current Medical Research and Opinion, Vol. 25, Iss. 12, 2009-12 ,pp. : 2951-2960

Informa Healthcare

Access to resources Recommend Favorite

Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study

By Miller Paul D.   Epstein Sol   Sedarati Farhad   Reginster Jean-Yves  

Current Medical Research and Opinion, Vol. 24, Iss. 1, 2008-01 ,pp. : 207-213

Informa Healthcare

Access to resources Recommend Favorite

Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO)

By Emkey Ronald   Koltun William   Beusterien Kathleen   Seidman Larry   Kivitz Alan   Devas Vipul   Masanauskaite Daiva  

Current Medical Research and Opinion, Vol. 21, Iss. 12, 2005-12 ,pp. : 1895-1903

Informa Healthcare

Access to resources Recommend Favorite